Cocrystal Pharma (COCP) Operating Expenses (2010 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Cocrystal Pharma was $10.44 million, down 17.9% year-over-year; for FY2025, it came in at $9.02 million, down 49.6% from FY2024.

• Annual Operating Expenses has declined for three consecutive years, with a five-year compound annual growth rate of -4.9% (FY2020 to FY2025).
• In prior years, Cocrystal Pharma's Operating Expenses was $17.88 million in FY2024 (-3.7%), $18.56 million in FY2023 (-52.2%), $38.83 million in FY2022 (+173.0%) and $14.22 million in FY2021 (+22.6%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses since Q3 2024.
• On a year-over-year basis, Operating Expenses increased in three of the last eight quarters, with an average decline of 17.2%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q2 2022, with growth of 538.1%; the weakest was Q2 2023, with a decline of 82.2%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $2.58 million (Q1 2026), $2.48 million (Q4 2025) and $2.09 million (Q3 2025).